Sign In
Last checked at 
5 Mar 2026 10:55
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Genflow Biosciences Plc
Successful Subscription to Raise £800,000 and PDMR Notifications
Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that it has raised £800,000 (the "Subscription") by way of an issue of 42,105,263 new ordinary shares of £0.0003 each ("Ordinary Shares") at a price of 1.9p per new Ordinary Share (the "Issue Price") by way of subscriptions ("Subscription Shares"), with each Subscription Share being accompanied by one warrant to subscribe for a new Ordinary Share.
The net proceeds from the Subscription are intended to support the advancement of Genflow's scientific programs and to provide sufficient cash runway, enabling the Company to engage in potential future licensing negotiations from a strong position.
Both Dr Eric Leire, Chief Executive Officer of the Company and Gad Berdugo, the newly appointed Chairman of the Company, have participated in the Subscription.
Subscribers in the Subscription have been issued with one warrant to subscribe for one new Ordinary Shares for every Subscription Share, with each Warrant entitling the holder to acquire one new Ordinary Share at the Issue Price at any time in the two-year period from issue (the "Warrants"). The Warrants will be in certificated form and none of the Warrants will be admitted to trading.
If exercised in full, the warrants would result in the issue of up to a further 42,105,263 ordinary shares and raise up to £800,000).
Admission, Conditionality and Total Voting Rights
Application will be made for the Subscription Shares to be admitted to trading ("Admission"). Admission is currently expected to become effective on or around 11 March 2026.
On Admission, the issued ordinary share capital of the Company will comprise 535,653,205 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, on Admission, the total number of Ordinary Shares and voting rights in the Company will be 535,653,205.
Following Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
"This financing strengthens our balance sheet, supports continued execution across our key development programs, and provides sufficient cash runway to approach potential licensing negotiations from a capitalized position."
PDMR Notifications
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
a) | Name | 1. Eric Leire 2. Gad Berdugo
| ||||||
2 | Reason for the notification | |||||||
a) | Position/status | Director/PDMR
| ||||||
b) | Initial notification /Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a) | Name | Genflow Biosciences Plc
| ||||||
b) | LEI | 213800HVOFXRXVEGDN62 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.0003 each
GB00BP2C3V08 | ||||||
b) | Nature of the transaction | Subscription for new Ordinary Shares | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
|
| ||||||
e) | Date of the transaction | 2 March 2025 | ||||||
f) | Place of the transaction | London | ||||||
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Jonathan.Paterson@Harbor-access.com |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
Follow the stocks
